Patents by Inventor Stuart Lutzker

Stuart Lutzker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20230201210
    Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: February 17, 2023
    Publication date: June 29, 2023
    Applicant: GENENTECH, INC.
    Inventors: Mark X. Sliwkowski, Scott Holden, Stuart Lutzker, Jay Tibbitts, Nelson L. Jumbe
  • TREATMENT OF CANCER WITH HER2XCD3 BISPECIFIC ANTIBODIES IN COMBINATION WITH ANTI-HER2 MAB
    Publication number: 20220098325
    Abstract: The present invention provides methods of treating of HER2-positive cancers (such as HER2-positive breast cancer and HER2-positive gastric cancers) using HER2 antibodies, such as a combination of a HER2 T cell-dependent bispecific antibody (TDB) with an additional HER2 antibody (e.g., trastuzumab).
    Type: Application
    Filed: September 13, 2021
    Publication date: March 31, 2022
    Inventors: Teemu T. JUNTTILA, Stuart LUTZKER
  • COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20190374547
    Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: August 21, 2019
    Publication date: December 12, 2019
    Applicant: GENENTECH, INC.
    Inventors: Mark X. Sliwkowski, Scott Holden, Stuart Lutzker, Jay Tibbitts, Nelson L. Jumbe
  • COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20170136026
    Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: January 24, 2017
    Publication date: May 18, 2017
    Inventors: Mark X. Sliwkowski, Scott Holden, Stuart Lutzker, Jay Tibbitts, Nelson L. Jumbe